首页 > 最新文献

Clinical Infectious Diseases最新文献

英文 中文
Diagnostic Accuracy of Chest X-ray Computer-Aided Detection Software for Detection of Prevalent and Incident Tuberculosis in Household Contacts.
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-18 DOI: 10.1093/cid/ciae528
Liana Macpherson, Sandra V Kik, Matteo Quartagno, Francisco Lakay, Marche Jaftha, Nombuso Yende, Shireen Galant, Saalikha Aziz, Remy Daroowala, Richard Court, Arshad Taliep, Keboile Serole, Rene T Goliath, Nashreen Omar Davies, Amanda Jackson, Emily Douglass, Bianca Sossen, Sandra Mukasa, Friedrich Thienemann, Taeksun Song, Morten Ruhwald, Robert J Wilkinson, Anna K Coussens, Hanif Esmail

Background: World Health Organization (WHO) tuberculosis (TB) screening guidelines recommend computer-aided detection (CAD) software for chest radiograph (CXR) interpretation. However, studies evaluating their diagnostic and prognostic accuracy are limited.

Methods: We conducted a prospective cohort study of household contacts of rifampicin-resistant TB in South Africa. Participants underwent baseline CXR and sputum investigation (routine [single spontaneous] and enhanced [additionally 2-3 induced]) for prevalent TB and follow-up for incident TB. Three CXR-CAD software products (CAD4TBv7.0, qXRv3.0.0, and Lunit INSIGHT v3.1.4.111) were compared. We evaluated their performance to detect routine and enhanced prevalent and incident TB, comparing performance with blood tests (Xpert MTB host-response, erythrocyte sedimentation rate, C-reactive protein, QuantiFERON) in a subgroup.

Results: 483 participants were followed up for 4.6 years (median). There were 23 prevalent (7 routinely diagnosed) and 38 incident TB cases. The AUC ROCs (95% CIs) to identify prevalent TB for CAD4TBv7.0, qXRv3.0.0, and Lunit INSIGHT v3.1.4.111 were .87 (.77-.96), .88 (.79-.97), and .91 (.83-.99), respectively. More than 30% with scores above recommended CAD thresholds who were bacteriologically negative on routine baseline sputum were subsequently diagnosed by enhanced sputum investigation or during follow-up. The AUC performance of baseline CAD to identify incident cases ranged between .60 and .65. Diagnostic performance of CAD for prevalent TB was superior to blood testing.

Conclusions: Our findings suggest that the potential of CAD-CXR screening for TB is not maximized as a high proportion of those above current thresholds, but with a negative routine confirmatory sputum, have true TB disease that may benefit intervention.

{"title":"Diagnostic Accuracy of Chest X-ray Computer-Aided Detection Software for Detection of Prevalent and Incident Tuberculosis in Household Contacts.","authors":"Liana Macpherson, Sandra V Kik, Matteo Quartagno, Francisco Lakay, Marche Jaftha, Nombuso Yende, Shireen Galant, Saalikha Aziz, Remy Daroowala, Richard Court, Arshad Taliep, Keboile Serole, Rene T Goliath, Nashreen Omar Davies, Amanda Jackson, Emily Douglass, Bianca Sossen, Sandra Mukasa, Friedrich Thienemann, Taeksun Song, Morten Ruhwald, Robert J Wilkinson, Anna K Coussens, Hanif Esmail","doi":"10.1093/cid/ciae528","DOIUrl":"https://doi.org/10.1093/cid/ciae528","url":null,"abstract":"<p><strong>Background: </strong>World Health Organization (WHO) tuberculosis (TB) screening guidelines recommend computer-aided detection (CAD) software for chest radiograph (CXR) interpretation. However, studies evaluating their diagnostic and prognostic accuracy are limited.</p><p><strong>Methods: </strong>We conducted a prospective cohort study of household contacts of rifampicin-resistant TB in South Africa. Participants underwent baseline CXR and sputum investigation (routine [single spontaneous] and enhanced [additionally 2-3 induced]) for prevalent TB and follow-up for incident TB. Three CXR-CAD software products (CAD4TBv7.0, qXRv3.0.0, and Lunit INSIGHT v3.1.4.111) were compared. We evaluated their performance to detect routine and enhanced prevalent and incident TB, comparing performance with blood tests (Xpert MTB host-response, erythrocyte sedimentation rate, C-reactive protein, QuantiFERON) in a subgroup.</p><p><strong>Results: </strong>483 participants were followed up for 4.6 years (median). There were 23 prevalent (7 routinely diagnosed) and 38 incident TB cases. The AUC ROCs (95% CIs) to identify prevalent TB for CAD4TBv7.0, qXRv3.0.0, and Lunit INSIGHT v3.1.4.111 were .87 (.77-.96), .88 (.79-.97), and .91 (.83-.99), respectively. More than 30% with scores above recommended CAD thresholds who were bacteriologically negative on routine baseline sputum were subsequently diagnosed by enhanced sputum investigation or during follow-up. The AUC performance of baseline CAD to identify incident cases ranged between .60 and .65. Diagnostic performance of CAD for prevalent TB was superior to blood testing.</p><p><strong>Conclusions: </strong>Our findings suggest that the potential of CAD-CXR screening for TB is not maximized as a high proportion of those above current thresholds, but with a negative routine confirmatory sputum, have true TB disease that may benefit intervention.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management, outcomes and predictors of mortality of Cryptococcus infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand.
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-18 DOI: 10.1093/cid/ciae630
Julien Coussement, Christopher H Heath, Matthew B Roberts, Rebekah J Lane, Tim Spelman, Olivia C Smibert, Anthony Longhitano, C Orla Morrissey, Blake Nield, Monica Tripathy, Joshua S Davis, Karina J Kennedy, Sarah A Lynar, Lucy C Crawford, Simeon J Crawford, Benjamin J Smith, Andrew P Gador-Whyte, Rose Haywood, Andrew A Mahony, Julia C Howard, Genevieve B Walls, Gabrielle M O'Kane, Matthew T Broom, Caitlin L Keighley, Olivia Bupha-Intr, Louise Cooley, Jennifer A O'Hern, Justin D Jackson, Arthur J Morris, Caroline Bartolo, Adrian R Tramontana, Katherine C Grimwade, Victor Au Yeung, Roy Chean, Emily Woolnough, Benjamin W Teh, Monica A Slavin, Sharon C-A Chen

Background: Limited data exist regarding outcomes of cryptococcosis in patients without HIV with few studies having compared outcomes of Cryptococcus gattii, versus C. neoformans, infection.

Methods: We conducted a retrospective study in 46 Australian and New Zealand hospitals to determine the outcomes of cryptococcosis in patients without HIV diagnosed between 2015 and 2019, and compared outcomes of C. gattii versus C. neoformans infections. Multivariable analysis identified predictors of mortality within one year.

Results: Of 426 patients, one-year all-cause mortality was 21%. C. gattii infection was associated with a lower mortality than C. neoformans (adjusted odds ratio [OR]: 0.47, 95% confidence interval [CI]: 0.23-0.95), whilst severe neurological symptoms at presentation was the strongest predictor of death (adjusted OR: 8.46, 95% CI: 2.99-23.98). Almost all (99.5%) patients with central nervous system (CNS) infection received induction antifungal therapy versus 27.7% of isolated pulmonary cryptococcosis. The commonest regimen in CNS disease was liposomal amphotericin B with flucytosine (93.8%, mean duration 31 ± 13 days). Among patients with CNS cryptococcosis, C. gattii infection was associated with higher risk of immune reconstitution inflammatory response (C-IRIS) than C. neoformans (21% versus 3%, p<0.001). Nineteen patients received amphotericin B-based re-induction therapy for suspected relapse but none had microbiological relapse. Serum cryptococcal antigen positivity and lung imaging abnormalities resolved slowly (resolution at one year in 25% and 34% of patients, respectively).

Conclusion: Compared with C. neoformans, C. gattii infection demonstrated lower mortality but higher C-IRIS risk in CNS infection. Severe neurological symptoms were the strongest predictor of mortality.

{"title":"Management, outcomes and predictors of mortality of Cryptococcus infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand.","authors":"Julien Coussement, Christopher H Heath, Matthew B Roberts, Rebekah J Lane, Tim Spelman, Olivia C Smibert, Anthony Longhitano, C Orla Morrissey, Blake Nield, Monica Tripathy, Joshua S Davis, Karina J Kennedy, Sarah A Lynar, Lucy C Crawford, Simeon J Crawford, Benjamin J Smith, Andrew P Gador-Whyte, Rose Haywood, Andrew A Mahony, Julia C Howard, Genevieve B Walls, Gabrielle M O'Kane, Matthew T Broom, Caitlin L Keighley, Olivia Bupha-Intr, Louise Cooley, Jennifer A O'Hern, Justin D Jackson, Arthur J Morris, Caroline Bartolo, Adrian R Tramontana, Katherine C Grimwade, Victor Au Yeung, Roy Chean, Emily Woolnough, Benjamin W Teh, Monica A Slavin, Sharon C-A Chen","doi":"10.1093/cid/ciae630","DOIUrl":"https://doi.org/10.1093/cid/ciae630","url":null,"abstract":"<p><strong>Background: </strong>Limited data exist regarding outcomes of cryptococcosis in patients without HIV with few studies having compared outcomes of Cryptococcus gattii, versus C. neoformans, infection.</p><p><strong>Methods: </strong>We conducted a retrospective study in 46 Australian and New Zealand hospitals to determine the outcomes of cryptococcosis in patients without HIV diagnosed between 2015 and 2019, and compared outcomes of C. gattii versus C. neoformans infections. Multivariable analysis identified predictors of mortality within one year.</p><p><strong>Results: </strong>Of 426 patients, one-year all-cause mortality was 21%. C. gattii infection was associated with a lower mortality than C. neoformans (adjusted odds ratio [OR]: 0.47, 95% confidence interval [CI]: 0.23-0.95), whilst severe neurological symptoms at presentation was the strongest predictor of death (adjusted OR: 8.46, 95% CI: 2.99-23.98). Almost all (99.5%) patients with central nervous system (CNS) infection received induction antifungal therapy versus 27.7% of isolated pulmonary cryptococcosis. The commonest regimen in CNS disease was liposomal amphotericin B with flucytosine (93.8%, mean duration 31 ± 13 days). Among patients with CNS cryptococcosis, C. gattii infection was associated with higher risk of immune reconstitution inflammatory response (C-IRIS) than C. neoformans (21% versus 3%, p<0.001). Nineteen patients received amphotericin B-based re-induction therapy for suspected relapse but none had microbiological relapse. Serum cryptococcal antigen positivity and lung imaging abnormalities resolved slowly (resolution at one year in 25% and 34% of patients, respectively).</p><p><strong>Conclusion: </strong>Compared with C. neoformans, C. gattii infection demonstrated lower mortality but higher C-IRIS risk in CNS infection. Severe neurological symptoms were the strongest predictor of mortality.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Anti-CD4 Autoantibodies on Immune Reconstitution in People With Advanced Human Immunodeficiency Virus
IF 11.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-18 DOI: 10.1093/cid/ciae562
Brian P Epling, Andrea Lisco, Maura Manion, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Gregg Roby, Virginia Sheikh, Stephen A Migueles, April Poole, Ainhoa Perez-Diez, Xiangdong Liu, V Koneti Rao, Peter D Burbelo, Irini Sereti
Background Despite suppressive antiretroviral therapy (ART), 15%–30% of people with human immunodeficiency virus (HIV) experience a limited recovery of CD4 T cells. Although autoantibodies against the CD4 receptor have previously been identified in people with HIV (PWH), little is known about their longitudinal impact on CD4 T-cell reconstitution. Methods Anti-CD4 autoantibodies were evaluated by the fluid-phase luciferase immunoprecipitation systems immunoassay in ART-naive people with advanced HIV (CD4 count ≤100 cells/µL), PWH with CD4 count &gt;200 cells/µL, long-term nonprogressors, people with idiopathic CD4 lymphopenia, people with autoimmune lymphoproliferative syndrome, and healthy volunteers without HIV. In the participants with advanced HIV, we assessed the association of anti-CD4 autoantibodies at ART initiation with CD4 recovery over a median follow-up of 192 weeks. Results Anti-CD4 autoantibodies were identified in 29% (61/210) of ART-naive participants with advanced HIV but were absent in people without HIV. Female PWH showed a 4-fold higher prevalence (P &lt; .001) of anti-CD4 autoantibodies compared to males. After ART initiation, people with advanced HIV with anti-CD4 autoantibodies exhibited an overall slower rate of CD4 reconstitution (5.8 vs 6.6 cells/µL/month, P = .007) and lower week 192 CD4 count (268 vs 355 cells/µL, P = .037). Incidental, clinically indicated immunosuppressive therapy in these participants was associated with an improved rate of CD4 reconstitution (P = .0019) and higher week 192 CD4 count (551 vs 268 cells/µL, P = .019). Conclusions People with advanced HIV harboring anti-CD4 autoantibodies at ART initiation demonstrated a slower rate and extent of CD4 reconstitution after 4 years. Incidental immunosuppressive therapy was associated with increased CD4 counts in these participants.
背景 尽管采用了抑制性抗逆转录病毒疗法(ART),但仍有15%-30%的人类免疫缺陷病毒(HIV)感染者的CD4 T细胞恢复有限。尽管之前已在艾滋病病毒感染者(PWH)中发现了抗 CD4 受体的自身抗体,但人们对其对 CD4 T 细胞重建的纵向影响知之甚少。方法 通过液相荧光素酶免疫沉淀系统免疫测定法对抗病毒治疗无效的晚期艾滋病病毒感染者(CD4 细胞数≤100 cells/µL)、CD4 细胞数&gt;200 cells/µL的艾滋病病毒感染者、长期非艾滋病病毒感染者、特发性 CD4 淋巴细胞减少症患者、自身免疫性淋巴组织增生综合征患者和未感染艾滋病病毒的健康志愿者中的抗 CD4 自身抗体进行了评估。在晚期 HIV 感染者中,我们评估了抗逆转录病毒疗法开始时抗 CD4 自身抗体与中位随访 192 周的 CD4 恢复之间的关系。结果 在 29%(61/210)接受抗逆转录病毒疗法的晚期 HIV 感染者中发现了抗 CD4 自身抗体,但在无 HIV 感染者中却没有发现。与男性相比,女性艾滋病病毒感染者的抗CD4自身抗体发生率高出4倍(P&P;lt; .001)。开始抗逆转录病毒疗法后,出现抗CD4自身抗体的晚期HIV感染者的CD4重建速度总体较慢(5.8 vs 6.6 cells/µL/月,P = .007),第192周的CD4计数也较低(268 vs 355 cells/µL,P = .037)。对这些参与者进行偶然的、有临床指征的免疫抑制治疗与CD4重建率的提高(P = .0019)和第192周CD4计数的升高(551 cells/µL vs 268 cells/µL,P = .019)有关。结论 开始接受抗逆转录病毒疗法时携带抗 CD4 自身抗体的晚期艾滋病病毒感染者在 4 年后 CD4 重组的速度和程度都会减慢。偶然的免疫抑制治疗与这些患者 CD4 细胞数的增加有关。
{"title":"Impact of Anti-CD4 Autoantibodies on Immune Reconstitution in People With Advanced Human Immunodeficiency Virus","authors":"Brian P Epling, Andrea Lisco, Maura Manion, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Gregg Roby, Virginia Sheikh, Stephen A Migueles, April Poole, Ainhoa Perez-Diez, Xiangdong Liu, V Koneti Rao, Peter D Burbelo, Irini Sereti","doi":"10.1093/cid/ciae562","DOIUrl":"https://doi.org/10.1093/cid/ciae562","url":null,"abstract":"Background Despite suppressive antiretroviral therapy (ART), 15%–30% of people with human immunodeficiency virus (HIV) experience a limited recovery of CD4 T cells. Although autoantibodies against the CD4 receptor have previously been identified in people with HIV (PWH), little is known about their longitudinal impact on CD4 T-cell reconstitution. Methods Anti-CD4 autoantibodies were evaluated by the fluid-phase luciferase immunoprecipitation systems immunoassay in ART-naive people with advanced HIV (CD4 count ≤100 cells/µL), PWH with CD4 count &amp;gt;200 cells/µL, long-term nonprogressors, people with idiopathic CD4 lymphopenia, people with autoimmune lymphoproliferative syndrome, and healthy volunteers without HIV. In the participants with advanced HIV, we assessed the association of anti-CD4 autoantibodies at ART initiation with CD4 recovery over a median follow-up of 192 weeks. Results Anti-CD4 autoantibodies were identified in 29% (61/210) of ART-naive participants with advanced HIV but were absent in people without HIV. Female PWH showed a 4-fold higher prevalence (P &amp;lt; .001) of anti-CD4 autoantibodies compared to males. After ART initiation, people with advanced HIV with anti-CD4 autoantibodies exhibited an overall slower rate of CD4 reconstitution (5.8 vs 6.6 cells/µL/month, P = .007) and lower week 192 CD4 count (268 vs 355 cells/µL, P = .037). Incidental, clinically indicated immunosuppressive therapy in these participants was associated with an improved rate of CD4 reconstitution (P = .0019) and higher week 192 CD4 count (551 vs 268 cells/µL, P = .019). Conclusions People with advanced HIV harboring anti-CD4 autoantibodies at ART initiation demonstrated a slower rate and extent of CD4 reconstitution after 4 years. Incidental immunosuppressive therapy was associated with increased CD4 counts in these participants.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"30 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship Between Acute Severe Acute Respiratory Syndrome Coronavirus 2 Viral Clearance and Long Coronavirus 2019 (Long COVID) Symptoms: A Cohort Study
IF 11.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-18 DOI: 10.1093/cid/ciae539
Carly Herbert, Annukka A R Antar, John Broach, Colton Wright, Pamela Stamegna, Katherine Luzuriaga, Nathaniel Hafer, David D McManus, Yukari C Manabe, Apurv Soni
Background The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral dynamics during acute infection and the development of long coronavirus disease 2019 (COVID-19), or “long COVID,” is largely unknown. Methods Between October 2021 and February 2022, 7361 people not known to have COVID-19 self-collected nasal swab samples for SARS-CoV-2 reverse-transcription polymerase chain reaction testing every 24–48 hours for 10–14 days. Participants whose first known SARS-CoV-2 infection was detected were surveyed for long COVID in August 2023. Their slopes of viral clearance were modeled using linear mixed effects models with random slopes and intercepts, and the relative risk (RR) of long COVID based on viral slopes was calculated using a log binomial model, adjusted for age, symptoms, and variant. Sex-based interaction terms were also evaluated for significance. Results A total of 172 participants were eligible for analyses, and 59 (34.3%) reported long COVID. The risk of long COVID with 3–4 symptoms (adjusted RR, 2.44 [95% confidence interval, .88–6.82]) and ≥5 symptoms (4.97 [1.90–13.0]) increased with each unit increase in slope of viral clearance. While the probability of long COVID increased with slowed viral clearance among women, the same relationship was not observed among men (interaction term: P = .02). Acute SARS-CoV-2 symptoms of abdominal pain (adjusted RR, 5.41 [95% confidence interval, 2.44–12.0]), nausea (3.01 [1.31–6.89]), and body aches (2.58 [1.26–5.30]) were most strongly associated with long COVID. Conclusions We observed that slower viral clearance rates during acute COVID-19 were associated with increased risk and more symptoms of long COVID . Early viral-host dynamics appear to be mechanistically linked to the development of long COVID.
背景 严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)急性感染期间的病毒动态与 2019 年长冠状病毒病(COVID-19)或 "长 COVID "的发展之间的关系在很大程度上是未知的。方法 在 2021 年 10 月至 2022 年 2 月期间,7361 名未被发现患有 COVID-19 的人自取了鼻拭子样本,在 10-14 天内每 24-48 小时进行一次 SARS-CoV-2 反转录聚合酶链反应检测。2023 年 8 月,对首次发现 SARS-CoV-2 感染者进行了长 COVID 调查。使用随机斜率和截距的线性混合效应模型对他们的病毒清除斜率进行建模,并使用对数二项式模型计算基于病毒斜率的长COVID相对风险(RR),并对年龄、症状和变异进行调整。还评估了基于性别的交互项的显著性。结果 共有 172 名参与者符合分析条件,其中 59 人(34.3%)报告了长 COVID。随着病毒清除率斜率每增加一个单位,出现 3-4 种症状(调整后 RR 值为 2.44 [95% 置信区间为 0.88-6.82])和≥5 种症状(4.97 [1.90-13.0])的长 COVID 风险就会增加。虽然女性出现长 COVID 的概率随着病毒清除率的减慢而增加,但在男性中却没有观察到同样的关系(交互项:P = .02)。急性 SARS-CoV-2 症状中的腹痛(调整后 RR 值为 5.41 [95% 置信区间为 2.44-12.0])、恶心(3.01 [1.31-6.89])和全身酸痛(2.58 [1.26-5.30])与长 COVID 的关系最为密切。结论 我们观察到,急性 COVID-19 期间较慢的病毒清除率与长期 COVID 的风险增加和症状增多有关。早期的病毒-宿主动态似乎与长程COVID的发展存在机理上的联系。
{"title":"Relationship Between Acute Severe Acute Respiratory Syndrome Coronavirus 2 Viral Clearance and Long Coronavirus 2019 (Long COVID) Symptoms: A Cohort Study","authors":"Carly Herbert, Annukka A R Antar, John Broach, Colton Wright, Pamela Stamegna, Katherine Luzuriaga, Nathaniel Hafer, David D McManus, Yukari C Manabe, Apurv Soni","doi":"10.1093/cid/ciae539","DOIUrl":"https://doi.org/10.1093/cid/ciae539","url":null,"abstract":"Background The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral dynamics during acute infection and the development of long coronavirus disease 2019 (COVID-19), or “long COVID,” is largely unknown. Methods Between October 2021 and February 2022, 7361 people not known to have COVID-19 self-collected nasal swab samples for SARS-CoV-2 reverse-transcription polymerase chain reaction testing every 24–48 hours for 10–14 days. Participants whose first known SARS-CoV-2 infection was detected were surveyed for long COVID in August 2023. Their slopes of viral clearance were modeled using linear mixed effects models with random slopes and intercepts, and the relative risk (RR) of long COVID based on viral slopes was calculated using a log binomial model, adjusted for age, symptoms, and variant. Sex-based interaction terms were also evaluated for significance. Results A total of 172 participants were eligible for analyses, and 59 (34.3%) reported long COVID. The risk of long COVID with 3–4 symptoms (adjusted RR, 2.44 [95% confidence interval, .88–6.82]) and ≥5 symptoms (4.97 [1.90–13.0]) increased with each unit increase in slope of viral clearance. While the probability of long COVID increased with slowed viral clearance among women, the same relationship was not observed among men (interaction term: P = .02). Acute SARS-CoV-2 symptoms of abdominal pain (adjusted RR, 5.41 [95% confidence interval, 2.44–12.0]), nausea (3.01 [1.31–6.89]), and body aches (2.58 [1.26–5.30]) were most strongly associated with long COVID. Conclusions We observed that slower viral clearance rates during acute COVID-19 were associated with increased risk and more symptoms of long COVID . Early viral-host dynamics appear to be mechanistically linked to the development of long COVID.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"48 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142841172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morbidity and Mortality Risk Among People With Human Immunodeficiency Virus and Central or Visceral Adiposity: A Targeted Literature Review. 人类免疫缺陷病毒感染者和中央或内脏脂肪过多者的发病率和死亡率风险:有针对性的文献综述。
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-18 DOI: 10.1093/cid/ciae543
Alison M Bjornson, Roger J Bedimo, Shelagh M Szabo, Hannah Rochon, Daniel Lee

Background: Given the known relationship between human immunodeficiency virus (HIV), antiretroviral therapies, and excess visceral adipose tissue (VAT), this review sought to characterize risk of negative health outcomes associated with excess VAT and increased waist circumference (WC) in people with HIV (PWH).

Methods: Comprehensive targeted literature searches were conducted in Medline/Embase (27 June 2022), identifying peer-reviewed articles and conference abstracts reporting on cohorts of PWH. Screening was guided by PECOS (Population, Exposure, Comparator, Outcomes, Study design) criteria. From the included studies, outcomes of interest including mortality and morbidity risk by VAT area and WC were extracted, overall, and by sex, race/ethnicity, and duration of HIV. Relationships between outcome and exposure variables were summarized.

Results: Thirty-five studies were included (sample size range: 31-1748 PWH). Twenty-five studies characterized the relationship between increased WC and negative health outcomes-cardiovascular disease (CVD), arteriosclerosis, hypertension, diabetes, hepatic fat and fibrosis, and cognitive impairment-among PWH. Fifteen studies reported on increased VAT and negative health outcomes: all-cause mortality, CVD, atherosclerosis, hepatic fat, and fibrosis. Importantly, there was a 2.1-times higher odds of 5-year all-cause mortality among PWH with the highest amount of VAT in the only study identified reporting on mortality. Among the studies characterizing the relationship between morbidity and VAT, for example, 1 found that, for each 10-cm2 increase in VAT, the risk of prevalent CVD increased by 1.05 (95% CI: 1.0-1.1) times.

Conclusions: WC may be a useful and cost-effective surrogate for visceral adiposity, which is an important marker of morbidity and mortality among PWH.

{"title":"Morbidity and Mortality Risk Among People With Human Immunodeficiency Virus and Central or Visceral Adiposity: A Targeted Literature Review.","authors":"Alison M Bjornson, Roger J Bedimo, Shelagh M Szabo, Hannah Rochon, Daniel Lee","doi":"10.1093/cid/ciae543","DOIUrl":"https://doi.org/10.1093/cid/ciae543","url":null,"abstract":"<p><strong>Background: </strong>Given the known relationship between human immunodeficiency virus (HIV), antiretroviral therapies, and excess visceral adipose tissue (VAT), this review sought to characterize risk of negative health outcomes associated with excess VAT and increased waist circumference (WC) in people with HIV (PWH).</p><p><strong>Methods: </strong>Comprehensive targeted literature searches were conducted in Medline/Embase (27 June 2022), identifying peer-reviewed articles and conference abstracts reporting on cohorts of PWH. Screening was guided by PECOS (Population, Exposure, Comparator, Outcomes, Study design) criteria. From the included studies, outcomes of interest including mortality and morbidity risk by VAT area and WC were extracted, overall, and by sex, race/ethnicity, and duration of HIV. Relationships between outcome and exposure variables were summarized.</p><p><strong>Results: </strong>Thirty-five studies were included (sample size range: 31-1748 PWH). Twenty-five studies characterized the relationship between increased WC and negative health outcomes-cardiovascular disease (CVD), arteriosclerosis, hypertension, diabetes, hepatic fat and fibrosis, and cognitive impairment-among PWH. Fifteen studies reported on increased VAT and negative health outcomes: all-cause mortality, CVD, atherosclerosis, hepatic fat, and fibrosis. Importantly, there was a 2.1-times higher odds of 5-year all-cause mortality among PWH with the highest amount of VAT in the only study identified reporting on mortality. Among the studies characterizing the relationship between morbidity and VAT, for example, 1 found that, for each 10-cm2 increase in VAT, the risk of prevalent CVD increased by 1.05 (95% CI: 1.0-1.1) times.</p><p><strong>Conclusions: </strong>WC may be a useful and cost-effective surrogate for visceral adiposity, which is an important marker of morbidity and mortality among PWH.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucocorticoid dosing and implications for vaccination: Evolution of global definitions.
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-18 DOI: 10.1093/cid/ciae613
Xia Wang, Cyra Patel, Michelle L Giles, Penelope Burns, Kristine Macartney, Benjamin Teh, Phoebe C Williams

Despite widespread adoption of "high-dose" glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety. In people receiving prednisone <7 mg/day, vaccine responses are maintained. In people on 'high-dose' glucocorticoids (>20 mg/day), antibody titres and seropositivity are reduced, whereas the impact of low- to medium-dose glucocorticoids (7 to 20 mg/day) on vaccine efficacy remains inconclusive. Due to inconsistent paediatric dosing regimens, data is insufficient to support a unified "high-dose" glucocorticoid threshold. Non-live vaccines are well tolerated in patients receiving glucocorticoids with rheumatic/inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those with severe immunodeficiencies. Clinicians should consider individual risk-benefit profiles, rather than following strict dosing thresholds, when curating immunisation programs for patients prescribed glucocorticoids.

{"title":"Glucocorticoid dosing and implications for vaccination: Evolution of global definitions.","authors":"Xia Wang, Cyra Patel, Michelle L Giles, Penelope Burns, Kristine Macartney, Benjamin Teh, Phoebe C Williams","doi":"10.1093/cid/ciae613","DOIUrl":"https://doi.org/10.1093/cid/ciae613","url":null,"abstract":"<p><p>Despite widespread adoption of \"high-dose\" glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety. In people receiving prednisone <7 mg/day, vaccine responses are maintained. In people on 'high-dose' glucocorticoids (>20 mg/day), antibody titres and seropositivity are reduced, whereas the impact of low- to medium-dose glucocorticoids (7 to 20 mg/day) on vaccine efficacy remains inconclusive. Due to inconsistent paediatric dosing regimens, data is insufficient to support a unified \"high-dose\" glucocorticoid threshold. Non-live vaccines are well tolerated in patients receiving glucocorticoids with rheumatic/inflammatory disorders, but enhanced reactogenicity after live vaccination may occur in those with severe immunodeficiencies. Clinicians should consider individual risk-benefit profiles, rather than following strict dosing thresholds, when curating immunisation programs for patients prescribed glucocorticoids.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study 实验室确诊流感住院儿童的抗病毒药物使用情况:一项前瞻性多中心监测研究
IF 11.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-17 DOI: 10.1093/cid/ciae573
James W Antoon, Justin Z Amarin, Olla Hamdan, Tess Stopczynski, Laura S Stewart, Marian G Michaels, John V Williams, Eileen J Klein, Janet A Englund, Geoffrey A Weinberg, Peter G Szilagyi, Jennifer E Schuster, Rangaraj Selvarangan, Christopher J Harrison, Julie A Boom, Leila C Sahni, Flor M Muñoz, Mary Allen Staat, Elizabeth P Schlaudecker, James D Chappell, Benjamin R Clopper, Heidi L Moline, Angela P Campbell, Andrew J Spieker, Samantha M Olson, Natasha B Halasa
Background Guidelines state that all hospitalized children with suspected or confirmed influenza receive prompt treatment with influenza-specific antivirals. We sought to determine the frequency of, and factors associated with, antiviral receipt among hospitalized children. Methods We conducted active surveillance of children presenting with fever or respiratory symptoms from 1 December 2016 to 31 March 2020 at 7 pediatric medical centers in the New Vaccine Surveillance Network. The cohort consisted of children hospitalized with influenza A or B confirmed by clinical or research testing. The primary outcome was frequency of antiviral receipt during hospitalization. We used logistic regression to obtain adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for factors associated with antiviral receipt. Results A total of 1213 children with laboratory-confirmed influenza were included. Overall, 652 children (53.8%) received an antiviral. Roughly 63.0% of children received clinical influenza testing. Among those with clinical testing, 67.4% received an antiviral. Factors associated with higher odds of antiviral receipt included hematologic (aOR = 1.76; 95% CI = 1.03–3.02) or oncologic/immunocompromising (aOR = 2.41; 95% CI = 1.13–5.11) disorders, prehospitalization antiviral receipt (aOR = 2.34; 95% CI = 1.49–3.67), clinical influenza testing (aOR = 3.07; 95% CI = 2.28–4.14), and intensive care unit admission (aOR = 1.53; 95% CI = 1.02–2.29). Symptom duration &gt;2 days was associated with lower odds of antiviral treatment (aOR = 0.40; 95% CI = .30–.52). Antiviral receipt varied by site with a 5-fold difference across sites. Conclusions Almost half of children hospitalized with influenza did not receive antivirals. Additional efforts to understand barriers to guideline adherence are crucial for optimizing care in children hospitalized with influenza.
背景指南规定,所有疑似或确诊流感的住院儿童都应及时接受流感特异性抗病毒药物治疗。我们试图确定住院儿童接受抗病毒治疗的频率及其相关因素。方法 我们从 2016 年 12 月 1 日至 2020 年 3 月 31 日在新疫苗监测网络的 7 个儿科医疗中心对出现发热或呼吸道症状的儿童进行了主动监测。队列包括经临床或研究检测证实患有甲型或乙型流感的住院儿童。主要结果是住院期间接受抗病毒治疗的频率。我们使用逻辑回归法得出了与接受抗病毒治疗相关因素的调整后几率比(aORs)和 95% 置信区间(CIs)。结果 共纳入了 1213 名经实验室确诊的流感患儿。共有 652 名儿童(53.8%)接受了抗病毒治疗。大约 63.0% 的儿童接受了临床流感检测。在接受临床检测的儿童中,有 67.4% 接受了抗病毒治疗。11)疾病、入院前接受抗病毒治疗(aOR = 2.34; 95% CI = 1.49-3.67)、临床流感检测(aOR = 3.07; 95% CI = 2.28-4.14)和入住重症监护室(aOR = 1.53; 95% CI = 1.02-2.29)。症状持续时间&gt;2天与较低的抗病毒治疗几率相关(aOR = 0.40; 95% CI = .30-.52)。不同地区接受抗病毒治疗的几率不同,相差 5 倍。结论 近半数流感住院患儿未接受抗病毒治疗。要想优化流感住院患儿的护理,就必须进一步努力了解遵守指南的障碍。
{"title":"Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study","authors":"James W Antoon, Justin Z Amarin, Olla Hamdan, Tess Stopczynski, Laura S Stewart, Marian G Michaels, John V Williams, Eileen J Klein, Janet A Englund, Geoffrey A Weinberg, Peter G Szilagyi, Jennifer E Schuster, Rangaraj Selvarangan, Christopher J Harrison, Julie A Boom, Leila C Sahni, Flor M Muñoz, Mary Allen Staat, Elizabeth P Schlaudecker, James D Chappell, Benjamin R Clopper, Heidi L Moline, Angela P Campbell, Andrew J Spieker, Samantha M Olson, Natasha B Halasa","doi":"10.1093/cid/ciae573","DOIUrl":"https://doi.org/10.1093/cid/ciae573","url":null,"abstract":"Background Guidelines state that all hospitalized children with suspected or confirmed influenza receive prompt treatment with influenza-specific antivirals. We sought to determine the frequency of, and factors associated with, antiviral receipt among hospitalized children. Methods We conducted active surveillance of children presenting with fever or respiratory symptoms from 1 December 2016 to 31 March 2020 at 7 pediatric medical centers in the New Vaccine Surveillance Network. The cohort consisted of children hospitalized with influenza A or B confirmed by clinical or research testing. The primary outcome was frequency of antiviral receipt during hospitalization. We used logistic regression to obtain adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for factors associated with antiviral receipt. Results A total of 1213 children with laboratory-confirmed influenza were included. Overall, 652 children (53.8%) received an antiviral. Roughly 63.0% of children received clinical influenza testing. Among those with clinical testing, 67.4% received an antiviral. Factors associated with higher odds of antiviral receipt included hematologic (aOR = 1.76; 95% CI = 1.03–3.02) or oncologic/immunocompromising (aOR = 2.41; 95% CI = 1.13–5.11) disorders, prehospitalization antiviral receipt (aOR = 2.34; 95% CI = 1.49–3.67), clinical influenza testing (aOR = 3.07; 95% CI = 2.28–4.14), and intensive care unit admission (aOR = 1.53; 95% CI = 1.02–2.29). Symptom duration &amp;gt;2 days was associated with lower odds of antiviral treatment (aOR = 0.40; 95% CI = .30–.52). Antiviral receipt varied by site with a 5-fold difference across sites. Conclusions Almost half of children hospitalized with influenza did not receive antivirals. Additional efforts to understand barriers to guideline adherence are crucial for optimizing care in children hospitalized with influenza.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"11 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintenance of Certification: Is a Knowledge-Based Assessment Really Necessary? 保持认证:基于知识的评估真的有必要吗?
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-17 DOI: 10.1093/cid/ciae270
Allan R Tunkel
{"title":"Maintenance of Certification: Is a Knowledge-Based Assessment Really Necessary?","authors":"Allan R Tunkel","doi":"10.1093/cid/ciae270","DOIUrl":"10.1093/cid/ciae270","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1331-1332"},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pleural Infection: Contemporary Microbiology Completing the Picture. 胸膜感染:当代微生物学》(Contemporary Microbiology Completing the Picture)。
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-17 DOI: 10.1093/cid/ciae103
Ruben Dyrhovden, Tomas Mikal Eagan, Øyvind Kommedal
{"title":"Pleural Infection: Contemporary Microbiology Completing the Picture.","authors":"Ruben Dyrhovden, Tomas Mikal Eagan, Øyvind Kommedal","doi":"10.1093/cid/ciae103","DOIUrl":"10.1093/cid/ciae103","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1533-1534"},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Socioeconomic Disparities and the Prevalence of Antimicrobial Resistance. 社会经济差异与抗菌药耐药性的流行。
IF 8.2 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-17 DOI: 10.1093/cid/ciae313
Lauren N Cooper, Alaina M Beauchamp, Tanvi A Ingle, Marlon I Diaz, Abdi D Wakene, Chaitanya Katterpalli, Tony Keller, Clark Walker, Seth Blumberg, Sanjat Kanjilal, Jonathan H Chen, Alexander P Radunsky, Zachary M Most, John J Hanna, Trish M Perl, Christoph U Lehmann, Richard J Medford

Background: The increased prevalence of antimicrobial-resistant (AMR) infections is a significant global health threat, resulting in increased disease, deaths, and costs. The drivers of AMR are complex and potentially impacted by socioeconomic factors. We investigated the relationships between geographic and socioeconomic factors and AMR.

Methods: We collected select patient bacterial culture results from 2015 to 2020 from electronic health records of 2 expansive healthcare systems within the Dallas-Fort Worth, Texas, metropolitan area. Among individuals with electronic health records who resided in the 4 most populous counties in Dallas-Fort Worth, culture data were aggregated. Case counts for each organism studied were standardized per 1000 persons per area population. Using residential addresses, the cultures were geocoded and linked to socioeconomic index values. Spatial autocorrelation tests identified geographic clusters of high and low AMR organism prevalence and correlations with established socioeconomic indices.

Results: We found significant clusters of AMR organisms in areas with high levels of deprivation, as measured by the area deprivation index (ADI). We found a significant spatial autocorrelation between ADI and the prevalence of AMR organisms, particularly for AmpC β-lactamase and methicillin-resistant Staphylococcus aureus, with 14% and 13%, respectively, of the variability in prevalence rates being attributable to their relationship with the ADI values of the neighboring locations.

Conclusions: We found that areas with a high ADI are more likely to have higher rates of AMR organisms. Interventions that improve socioeconomic factors such as poverty, unemployment, decreased access to healthcare, crowding, and sanitation in these areas of high prevalence may reduce the spread of AMR.

背景:抗菌药物耐药性(AMR)感染率的上升是一个重大的全球健康威胁,导致发病率、死亡率和成本增加。AMR的驱动因素十分复杂,并可能受到社会经济因素的影响。我们研究了地理和社会经济因素与 AMR 之间的关系:我们从德克萨斯州达拉斯-沃斯堡大都会区(DFW)内两家大型医疗保健系统的电子健康记录(EHR)中收集了 2015 年至 2020 年期间部分患者的细菌培养结果。对居住在达拉斯-沃斯堡(DFW)四个人口最多的县中有电子健康记录的个人的培养数据进行了汇总。所研究的每种生物的病例数均按每千人每地区人口进行标准化。使用居住地址对培养物进行地理编码,并将其与社会经济指数值联系起来。空间自相关检验确定了AMR微生物流行率高和低的地理群组,以及与既定社会经济指数的相关性:结果:我们发现,在以地区贫困指数(ADI)衡量的贫困程度较高的地区,AMR病原菌存在明显的集群。我们发现 ADI 与 AMR 微生物流行率之间存在明显的空间自相关性,尤其是在 AmpC 和 MRSA 方面,流行率的变化分别有 14% 和 13% 与邻近地区的 ADI 值有关:我们发现,ADI 值高的地区更有可能出现较高的 AMR 微生物感染率。在这些高发病率地区采取干预措施,改善贫困、失业、医疗服务减少、拥挤和卫生条件差等社会经济因素,可能会减少 AMR 的传播。
{"title":"Socioeconomic Disparities and the Prevalence of Antimicrobial Resistance.","authors":"Lauren N Cooper, Alaina M Beauchamp, Tanvi A Ingle, Marlon I Diaz, Abdi D Wakene, Chaitanya Katterpalli, Tony Keller, Clark Walker, Seth Blumberg, Sanjat Kanjilal, Jonathan H Chen, Alexander P Radunsky, Zachary M Most, John J Hanna, Trish M Perl, Christoph U Lehmann, Richard J Medford","doi":"10.1093/cid/ciae313","DOIUrl":"10.1093/cid/ciae313","url":null,"abstract":"<p><strong>Background: </strong>The increased prevalence of antimicrobial-resistant (AMR) infections is a significant global health threat, resulting in increased disease, deaths, and costs. The drivers of AMR are complex and potentially impacted by socioeconomic factors. We investigated the relationships between geographic and socioeconomic factors and AMR.</p><p><strong>Methods: </strong>We collected select patient bacterial culture results from 2015 to 2020 from electronic health records of 2 expansive healthcare systems within the Dallas-Fort Worth, Texas, metropolitan area. Among individuals with electronic health records who resided in the 4 most populous counties in Dallas-Fort Worth, culture data were aggregated. Case counts for each organism studied were standardized per 1000 persons per area population. Using residential addresses, the cultures were geocoded and linked to socioeconomic index values. Spatial autocorrelation tests identified geographic clusters of high and low AMR organism prevalence and correlations with established socioeconomic indices.</p><p><strong>Results: </strong>We found significant clusters of AMR organisms in areas with high levels of deprivation, as measured by the area deprivation index (ADI). We found a significant spatial autocorrelation between ADI and the prevalence of AMR organisms, particularly for AmpC β-lactamase and methicillin-resistant Staphylococcus aureus, with 14% and 13%, respectively, of the variability in prevalence rates being attributable to their relationship with the ADI values of the neighboring locations.</p><p><strong>Conclusions: </strong>We found that areas with a high ADI are more likely to have higher rates of AMR organisms. Interventions that improve socioeconomic factors such as poverty, unemployment, decreased access to healthcare, crowding, and sanitation in these areas of high prevalence may reduce the spread of AMR.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"1346-1353"},"PeriodicalIF":8.2,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Infectious Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1